

November 14, 2022

Ref : KIMIABL/COMP/BSE/22-23/49

To
Department of Corporate Affairs- Listing
BSE Limited
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]
Sub: Outcome of the Board Meeting.

Dear Sir/Madam,

The meeting of Board of Directors of the Company was held today on Monday, November 14, 2022 at 4.00 p.m (IST) at the corporate office of the Company situated at 974, 9th floor Aggarwal Millennium Tower-II Netaji Subhash Place Pitampura Delhi-110034.

1. Approval of un-audited financial results of the Company, on standalone basis, as at/for the half year ended September 30, 2022, in accordance with Regulation 33 of SEBI (Listing Obligation and Disclosure) Requirements) Regulations, 2015.
The Limited Review Report dated November 14, 2022 issued by the Statutory Auditor of the Company was taken on record. (Copy attached as Annexure A)


We request you to take the above information on record and disseminate the same on your website.

The meeting of Board of Directors concluded at 5.30 pm (IST).

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**


Lakshay Prakash
Company Secretary & Compliance Officer
PLACE: New Delhi
Encl.: a/a



KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

Page 1 of 4

STATEMENT OF CASH FLOWS

Particulars	For the year ended September 30, 2022 (Unaudited)	For the year ended September 30, 2021 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit before tax	37.10	(126.26)
Adjustment for :		
Depreciation and amortization expense	152.11	141.45
Finance costs	193.50	168.40
Gain on fair value of investment in mutual funds	(0.01)	(0.22)
Interest income	(0.85)	(0.80)
Deferred revenue income	(12.48)	(24.95)
Unrealised (gain)/loss on foreign currency transactions and translations	63.51	(0.03)
Operating Profit Before Working Capital Changes	442.88	157.59
Adjustments for:		
(Increase) / Decrease in inventories	(1,024.07)	(272.96)
(Increase) / Decrease in trade and other receivables	(727.08)	978.81
Increase / (Decrease) in trade and other payables	679.14	(483.50)
Cash Generated From Operations	(629.13)	379.94
Less : Income tax paid / (refunds)	(3.11)	(1.44)
Net Cash From Operating Activities	(632.24)	378.50
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital advances	(182.21)	(199.57)
Proceeds from sales of property, plant & equipment	-	16.31
Net inflow / (outflow) in fixed deposits	0.13	9.23
Purchase of current investments	(0.20)	-
Interest received	0.08	0.80
Net Cash Used In Investing Activities	(182.20)	(173.23)
C. Cash Flow from Financing Activities		
Receipts from non current borrowings	581.00	428.41
Repayment of non current borrowings	(503.68)	(574.47)
Net proceeds of current borrowings	831.45	51.84
Finance costs paid	(84.89)	(148.22)
Net Cash Used in Financing Activities	823.88	(242.44)
Net Increase / (Decrease) in Cash and Cash Equivalents	9.44	(37.17)
Cash and Cash Equivalents at the beginning of the period	20.49	58.66
Cash and Cash Equivalents at the end of the period	29.93	21.49

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14.11.2022

FOR KIMIA BIOSCIENCES LIMITED


Sameer Goel
(Managing Director & CEO)
DIN - 00161786

Date : November 14, 2022
Place : New Delhi



S. No.	Particulars	Quarter ended			Half Year ended		
		30-09-2022	30-06-2022	30-09-2021	30-09-2022	30-09-2021	Year Ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	4,046.58	3,658.48	3,092.71	7,705.06	6,179.62	12,490.09
II	Other Income	13.35	45.25	32.14	58.60	49.53	93.22
III	Total Income (I+II)	4,059.93	3,703.73	3,124.85	7,763.66	6,229.14	12,583.30
IV	Expenses:						
a)	Cost of materials consumed	3,382.84	2,865.58	2,447.13	6,248.42	4,529.33	9,603.31
b)	Change in inventories of finished goods and work-in-progress	(363.29)	(292.30)	(183.50)	(655.59)	(133.28)	(376.96)
c)	Employee benefits expenses	367.83	386.27	368.56	754.10	733.76	1,508.05
d)	Finance costs	110.43	83.07	90.17	193.50	168.40	364.08
e)	Depreciation and amortisation expense	82.39	79.72	76.25	162.11	141.46	294.10
f)	Other expenses	591.56	432.45	496.39	1,024.00	915.75	1,692.55
V	Total Expenses (IV)	4,171.76	3,554.79	3,294.99	7,726.56	6,355.41	13,085.13
VI	Profit/(loss) Before Tax (IV-V)	(111.83)	148.94	(170.15)	37.09	(126.26)	(501.83)
VII	Tax expenses:						
a)	Current Tax	-	-	-	-	-	-
b)	Deferred Tax charge / (reversal)	(28.98)	38.72	(43.36)	9.74	(31.23)	(131.52)
VIII	Profit/(loss) for the period (VI-VII)	(82.84)	110.22	(126.79)	27.36	(95.03)	(370.32)
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
-	- Remeasurement of defined benefit plans	-	-	-	-	-	9.26
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	-
X	Total Comprehensive Income for the period (VIII+IX)	(82.84)	110.22	(126.79)	27.36	(95.03)	(361.05)
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						1,015.70
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	(0.18)	0.23	(0.27)	0.06	(0.20)	(0.78)
	Diluted in Rs.	(0.18)	0.23	(0.27)	0.06	(0.20)	(0.78)

STATEMENT OF ASSETS, EQUITY and LIABILITIES

S. No.	Particulars	As at 30-09-2022 (Unaudited)	As at 31-03-2022 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	3490.20	3508.23
	Other Intangible Assets	12.16	14.48
	Deferred Tax Assets (Net)	81.38	90.83
	Financial Assets		
	(i) Other Non Current Financial Assets	20.28	20.28
	Other Non-current Assets	13.05	8.30
2	Current Assets		
	Inventories	4725.89	3701.81
	Financial Assets		
	(i) Investment	6.05	6.04
	(ii) Trade Receivables	3585.24	3020.14
	(iii) Cash and Cash Equivalents	29.93	20.49
	(iv) Bank balances other than (iii) above	31.12	31.24
	(v) Other Current Financial Assets	187.48	100.73
	Current Tax Assets (Net)	80.11	77.00
	Other Current Assets	366.47	349.57
	Total Assets	12629.36	10949.14
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	1043.08	1015.70
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2640.47	2444.56
	(ii) Other financial liabilities	510.77	488.77
	Deferred Tax Liabilities (Net)	0.00	-
	Provisions	115.26	112.07
	Other Non-Current Liabilities	209.77	234.73
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2329.86	1617.00
	(ii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	15.52	19.10
	b. Total Outstanding due to other than Micro and Small Enterprises	4855.43	4001.52
	(iii) Other Financial Liabilities	324.74	313.00
	Other Current Liabilities	106.16	224.40
	Provisions	5.16	5.16
	Total Equity and Liabilities	12629.36	10949.14



Independent Auditor's Review Report on Unaudited Financial Results for the quarter and half year ended September 30, 2022 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended


To the Board of Directors of Kimia Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Limited ("the Company") for the quarter and half year ended September 30, 2022. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Noida (Delhi – NCR)
Date: November 14, 2022



For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E


Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 22088926BDBWRK2627